{Reference Type}: Journal Article
{Title}: Survival outcomes and treatment experience of 124 patients with primary central nervous system lymphoma.
{Author}: Tang Z;Wu G;Tan F;Long Y;Hong J;Lyu Z;Wei R;
{Journal}: Strahlenther Onkol
{Volume}: 0
{Issue}: 0
{Year}: 2024 Mar 11
{Factor}: 4.033
{DOI}: 10.1007/s00066-024-02219-5
{Abstract}: <B>OBJECTIVE: </B>Primary central nervous system lymphoma (PCNSL) is a rare malignancy of the central nervous system with high invasiveness. There is little consensus on the treatment of PCNSL. This study retrospectively studied data from PCNSL patients in a single center to summarize treatment experience and explore prognostic factors.<BR><B>METHODS: </B>Survival curves were drawn using the Kaplan-Meier method and prognostic factors were analyzed using Cox's hazards model.<BR><B>RESULTS: </B>In multivariate analysis, cerebrospinal fluid lactic acid dehydrogenase (CSF LDH; p = 0.005 and p = 0.002), neutrophil to lymphocyte ratio (NLR; p = 0.014 and p = 0.038), and completion of four cycles of induction therapy (p < 0.001and p < 0.001) were significant and independent predictors of overall survival (OS) and progression-free survival (PFS), respectively.<BR><B>CONCLUSIONS: </B>On the basis of this study, we propose that PCNSL patients should receive early induction therapy with sufficient cycles. Subsequent consolidation therapy can prevent relapses and improve survival. In patients with PCNSL, the independent prognostic factors for OS and PFS were CSF LDH level, NLR, and full cycles of induction therapy.